Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2016

View Archived Issues

Abeona Therapeutics enters collaboration for research on epidermolysis bullosa

Novo Nordisk offers overview of second quarter 2016

Omeros' MASP-3 inhibitor shows efficacy in PNH model

ANXA1 signaling as a novel therapeutic target for the resolution of immune dysfunction in HIV

FDA approves Heron Therapeutics' Sustol for chemotherapy-induced nausea and vomiting

PET-based platform to screen and evaluate potential nanoparticles for photothermal treatment

ZEB1-induced EMT contributes to early pathogenesis and metastatic potential in lung cancer

Phase II study of vTv Therapeutics' TTP-399 mets primary endpoint

Pfizer patents retinoid RORgamma t receptor antagonists and IL-17 production inhibitors

Jn Therapeutics develops JAK1 inhibitors

Otsuka Pharmaceutical profiles progress of second quarter 2016

Roche patent reveals anti-HBV agents

FDA grants priority review to deflazacort NDAs for DMD

BMS to reacquire rights to ASLAN-002

JDRF enters development and discovery collaboration with Pacific Diabetes Technologies

Selvita signs a medicinal chemistry collaboration with UCSF

New international collaborations to tackle antimicrobial resistance

AstraZeneca announces increased equity interest in Moderna Therapeutics

Genmab and Gilead Sciences enter DuoBody license agreement

Oncolytics Biotech reports further data from phase II study of Reolysin in NSCLC

FDA accepts Amphivena Therapeutics' IND for AMV-564

PharmaMar receives response on the CORAIL trial of PM-1183

ADDC announces third call for proposals in partnership with AstraZeneca

Protalix BioTherapeutics reports efficacy and safety data from phase I/II study of PRX-102

HHS awards funding to advance Hologic's Procleix Zika Virus Assay

MPC-300-IV shows dose-related improvements in phase II trial in biologic refractory RA